Is ContraFect Corp. (CFRXQ) a Buy, Sell, or Hold?
OTC : CFRXQ
ContraFect Corp.
$1e-05 USD
$0 (0.0%)
- Volume
- 15K
- Average Volume
- 12.67K
- Market Capitalization
- $107
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.85
Company Overview
OTC
Roger J. Pomerantz
Biotechnology
Healthcare
CFRXQ
23
US
USD
Liquidity Metrics
-0.24
0.85
0.85
0.43
0.00
Sales & Valuation
-$
0.00
0.00
0.00
-88.30
Profitability
-$124.97
-$65.15M
0.00%
0.00%
-347.26%
-315.07%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
1 Analysts
%
Financial Health Scores
-63.85
0/9
-$5.8M
$9.12M
$14.88M
-$30.21M
Key Metrics (TTM)
-$6.03M
0.00
0.09
0.85
-347.26%
-4817.02%
-1249676326.68%
-43024299.07%
-32402 days
Company Executives
No executive data available.
Poll Results
No votes yet today — be the first to share your view!
About ContraFect Corp. (OTC:CFRXQ) Stock
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, ... the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Frequently Asked Questions
-
What is the current ContraFect Corp. (CFRXQ) stock price?
-
ContraFect Corp.(OTC:CFRXQ) stock price is $1e-05 in the last trading session. During the trading session, CFRXQ stock reached the peak price of $0.0005 while $0.00001 was the lowest point it dropped to. The percentage change in CFRXQ stock occurred in the recent session was 0.0% while the dollar amount for the price change in CFRXQ stock was $0.
-
CFRXQ's industry and sector of operation?
-
The OTC listed CFRXQ is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CFRXQ?
-
|
|
|
|
| -
How many employees does CFRXQ have?
-
Number of CFRXQ employees currently stands at 23. CFRXQ operates from 28 Wells Avenue, Yonkers, NY 10701, US.
-
Link for CFRXQ official website?
-
Official Website of CFRXQ is: http://aces.gg
-
How do I contact CFRXQ?
-
CFRXQ could be contacted at phone #914 207 2300 and can also be accessed through its website. CFRXQ operates from 28 Wells Avenue, Yonkers, NY 10701, US.
-
How many shares of CFRXQ are traded daily?
-
The average number of CFRXQ shares traded daily for last 3 months was 12.67K.
-
What is the market cap of CFRXQ currently?
-
The market value of CFRXQ currently stands at $107 with its latest stock price at $1e-05